In the last trading session, 1.92 million shares of the Organogenesis Holdings Inc (NASDAQ:ORGO) were traded, and its beta was 1.75. Most recently the company’s share price was $5.42, and it changed around $0.54 or 11.07% from the last close, which brings the market valuation of the company to $687.41M. ORGO currently trades at a discount to its 52-week high of $6.71, offering almost -23.8% off that amount. The share price’s 52-week low was $2.16, which indicates that the current value has risen by an impressive 60.15% since then. We note from Organogenesis Holdings Inc’s average daily trading volume that its 10-day average is 1.22 million shares, with the 3-month average coming to 1.73 million.
Organogenesis Holdings Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended ORGO as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Organogenesis Holdings Inc is expected to report earnings per share of -0.03 for the current quarter.
Organogenesis Holdings Inc (NASDAQ:ORGO) trade information
Instantly ORGO has showed a green trend with a performance of 11.07% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 5.51 on recent trading dayincreased the stock’s daily price by 1.63%. The company’s shares are currently up 69.37% year-to-date, but still up 9.05% over the last five days. On the other hand, Organogenesis Holdings Inc (NASDAQ:ORGO) is 68.85% up in the 30-day period. We can see from the shorts that 8.62 million shares have been sold at a short interest cover period of 2.9 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 9.67% from its current value. Analyst projections state that ORGO is forecast to be at a low of $6 and a high of $6.
Organogenesis Holdings Inc (ORGO) estimates and forecasts
The year-over-year growth rate is expected to be 1.29%, up from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 90.77M in revenue for the current quarter. 3 analysts expect Organogenesis Holdings Inc to make 102.17M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 109.98M and 130.23M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -17.47%. Forecasts for the next quarter put sales growth at -21.55%.
Organogenesis Holdings Inc (NASDAQ:ORGO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 46.66% of Organogenesis Holdings Inc shares, and 49.76% of them are in the hands of institutional investors. The stock currently has a share float of 93.29%. Organogenesis Holdings Inc stock is held by 158.0 institutions, with MORGAN STANLEY being the largest institutional investor. By 2024-06-30, it held 8.7318% of the shares, which is about 11.58 million shares worth $32.41 million.
SOLEUS CAPITAL MANAGEMENT, L.P., with 8.6888% or 11.52 million shares worth $32.25 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.95 shares worth $10.58 million, making up 1.54% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 1.46 shares worth around $7.92 million, which represents about 1.15% of the total shares outstanding.
